Home > Rheumatology > ACR 2020 > Spondyloarthritis – The Beat Goes On > Promising novel treatment option for psoriatic arthritis

Promising novel treatment option for psoriatic arthritis

Presented By
Prof. Philip J. Mease, University of Washington, USA
ACR 2020
The small molecule deucravacitinib led to a significantly better ACR20 response and better physical function independent of prior TNF inhibitor use in 180 psoriatic arthritis patients in a randomised, double-blind, placebo-controlled phase 2 trial. Deucravacitinib (formerly BMS-986165) is a novel oral tyrosine kinase (TYK)2 inhibitor. It is far more selective than other drugs in this class, as it does not bind to the kinase domain, but only to a regulatory domain of TYK2 outside the active site [1]. Thus, it inhibits downstream pathways important in psoriasis and psoriatic arthritis (PsA) pathophysiology, including interleukin (IL)-23 and IL-22, while limiting off-target effects observed with other kinase inhibitors. In an earlier phase 2 dose-finding study in psoriasis, this drug showed to be significantly more effective compared with placebo: 67-75% of patients treated with ≥3 mg deucravacitinib achieved a ≥75% reduction from baseline...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on